Movano Inc. (NASDAQ:MOVE) Q4 2022 Earnings Call Transcript

In regards to future financings, I guess what we’d say is that we have several catalysts in front of us. Obviously, going from pre-revenue to revenue is a big deal with the launch of the Evie Ring. We’re very excited about that. We’re also partnering, as noted on multiple occasions now on this call, with six major players across health and consumer in regards to our betas, which is quite exciting for us and shows there’s a lot of interest in what we’re doing. We’ll also be filing for our first FDA clearances, as we talked about, this spring. And we’ll be looking forward to bringing this wearable medical device to the market, which will certainly be a differentiator. And then, obviously, we’re moving forward with our single chip clinical studies as we talked about earlier as well trying to solve for the holy grails of glucose monitoring on a non-invasive basis and blood pressure monitoring without a cuff.

We’ve had great support from our investors to-date obviously, and we’re just focused on what’s in our control and executing. And we know that we’re obviously going after quite a significant opportunity. Okay. Let’s see. Operator, are there any more questions for — from the phone lines?

Operator: There are no more further questions at this time.

J. Cogan: Okay. Well, I think that pretty much wraps it up for us for today. Thank you for your time, everyone. As a reminder, you can stay connected and up to date on Movano Health news and events by checking out our investor website at ir.movano.com.

Operator: Thank you. This concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation, and have a wonderful day.